Eckert & Ziegler Reorganizes its Production Sites
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Real Estate - Sale of Belgian special purpose property initiated If the authority approves the transfer as requested, this would result in a release of the disposal reserves previously held for the Belgian production building. This change in the balance sheet would result in a one-off income of 2.7 Mio. EUR for Eckert & Ziegler. Your contact: Information and Explanation of the Issuer to this News: With the merger of the Belgian prostate implant specialist IBt in 2008, Eckert & Ziegler BEBIG SA took over a production site where cyclotrons were used to produce precursors for low-level radioactive implants. Since new production sites are planned in Asia and North America as part of a realignment and globalization of the Pharmaceuticals division, Eckert & Ziegler is now divesting from this special property.
05-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | karolin.riehle@ezag.de |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 991105 |
End of Announcement | DGAP News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: